Indivior Reports Strong Q1 Results, Raises Full-Year 2026 Guidance, and Executes Share Buyback
Summary
Indivior reported strong Q1 2026 financial results, including a 19% YoY revenue increase and 112% YoY Adjusted EBITDA growth, leading to a significant raise in its full-year 2026 guidance. The company also repurchased $125 million in shares and completed a $500 million convertible notes offering, while discontinuing two pipeline programs.
Key Events
-
Strong Q1 Financial Performance
Indivior reported Q1 2026 total net revenue of $317 million, up 19% year-over-year, driven by a 32% increase in SUBLOCADE net revenue to $232 million. Adjusted EBITDA surged 112% year-over-year to a record $164 million.
-
Raised Full-Year 2026 Guidance
The company raised its full-year 2026 guidance, now expecting total net revenue between $1,215 million and $1,285 million, and Adjusted EBITDA between $620 million and $660 million, representing a significant increase from prior estimates.
-
Significant Share Repurchase
Indivior repurchased approximately 4 million shares for $125 million during Q1 2026, with $275 million remaining under its $400 million share repurchase program authorized in February 2026.
-
Pipeline Adjustments
The company announced it will not pursue Phase 3 development for INDV-6001 and will seek external business development opportunities for INDV-2000 after its Phase 2 study did not meet the primary endpoint.
Analysis
Indivior Pharmaceuticals delivered robust first-quarter results, significantly exceeding expectations and leading to a substantial increase in its full-year 2026 financial guidance. The strong performance of SUBLOCADE, the company's key long-acting injectable for opioid use disorder, drove revenue and EBITDA growth. This positive financial momentum is further supported by disciplined capital allocation, including the execution of a significant share repurchase program and the successful completion of a convertible notes offering to refinance debt. While the company announced the discontinuation of internal development for two pipeline assets (INDV-6001 and INDV-2000), this move is framed as a strategic prioritization, allowing focus on the high-growth SUBLOCADE franchise. The market is likely to view the strong financial performance and capital return favorably, reinforcing the positive sentiment that has driven the stock near its 52-week high.
At the time of this filing, INDV was trading at $37.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $10.63 to $38.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.